[Observation on efficacy of puerarin in treating diabetic retinopathy].
OBJECTIVE
Using promoting blood circulation to remove stasis principle to observe arteria and vena centralis retinae blood flow indexes, and hemorrheology of diabetic retinopathy patients with Puerarin.


METHODS
Thirty patients with diabetic retinopathy were randomly divided into the treated group (n = 15) and the control group (n = 15). The treated group were given Puerarin 400 mg per day intravenously dripping. The control group were given Mikebao 500 micrograms intramuscularly, once per day. Both groups were taken 3 consecutive weeks as one treatment course. Two courses later, observing hemorrheologic parameters, arteria and vena centralis retinae blood flow indexes.


RESULTS
Comparing before and after treatment the RBC aggregation index, the whole blood viscosity rate, plasma viscosity rate, fibrinogen and erythrocyte sedimentation rate, have improved obviously (P < 0.05, P < 0.01). Comparing with the control group, there was significant difference (P < 0.05, P < 0.01). The difference of treated group between before and after treatment, the peak systolic velocity (PSV) of arteria centralis retinae, their end diastolic volume (EDV), the acceleration (A), the central retinal vein reflux velocity (CRV) have improved respectively. Naked eye visions were also improved, comparing with the control group, the difference was significant (P < 0.01).


CONCLUSIONS
Puerarin can reduce blood viscosity, improve microcirculation, and plays a positive therapeutic role in diabetic retinopathy.
Ren
P
P
Affiliated Hospital of Liaoning College of Traditional Chinese Medicine, Shenyang (110032).
Hu
H
H
Zhang
R
R
D000328:Adult; D000368:Aged; D001809:Blood Viscosity / Q000187:drug effects*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D003930:Diabetic Retinopathy / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D006801:Humans; D007529:Isoflavones / Q000627:therapeutic use*; D008297:Male; D008833:Microcirculation / Q000187:drug effects; D008875:Middle Aged; D014665:Vasodilator Agents / Q000627:therapeutic use*
D007529:Isoflavones; D014665:Vasodilator Agents; C033607:puerarin